Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Bellesoeur · SciRah

Researcher profile · Semantic Scholar

A. Bellesoeur

Share profile

A. Bellesoeur — researcher profile on SciRah

h-index: 18
Works: 56
Citations: 1,380

Most-cited papers

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
D. Farge, C. Frère, J. Connors, A. Khorana +102 more
2022The Lancet Oncology333 citations Open access
Semantic Scholar
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
T. Valentin, A. Le Cesne, I. Ray-Coquard, A. Italiano +12 more
2016European Journal of Cancer145 citations
Semantic Scholar
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
D. Damotte, S. Warren, J. Arrondeau, P. Boudou-Rouquette +20 more
2019Journal of Translational Medicine127 citations Open access
Semantic Scholar
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
P. Vuagnat, M. Frelaut, Toulsie Ramtohul, C. Basse +13 more
2020Breast Cancer Research118 citations Open access
Semantic Scholar
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
A. Puszkiel, G. Noé, A. Bellesoeur, N. Kramkimel +6 more
2018Clinical Pharmacokinetics101 citations
Semantic Scholar
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
A. Bellesoeur, Edith Carton, J. Alexandre, F. Goldwasser +1 more
2017Drug Design, Development and Therapy62 citations Open access
Semantic Scholar
Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.
A. Bellesoeur, A. Thomas-Schoemann, M. Allard, D. Smadja +4 more
2018Critical reviews in oncology/hematology58 citations
Semantic Scholar
Liquid chromatography‐tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non‐small cell lung cancer patients
Rafael Reis, L. Labat, M. Allard, P. Boudou-Rouquette +9 more
2018Journal of Pharmaceutical and Biomedical Analysis54 citations
Semantic Scholar
The impact of body composition parameters on severe toxicity of nivolumab.
L. Hirsch, A. Bellesoeur, P. Boudou-Rouquette, J. Arrondeau +10 more
2019European Journal of Cancer39 citations Open access
Semantic Scholar
Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
A. Bellesoeur, E. Ollier, M. Allard, L. Hirsch +15 more
2019Cancers33 citations Open access
Semantic Scholar
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients
C. Basse, Sarah Diakité, V. Servois, M. Frélaut +19 more
2020JNCI Cancer Spectrum31 citations Open access
Semantic Scholar
Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study
L. Cabel, B. Blanchet, A. Thomas-Schoemann, O. Huillard +10 more
2018Fundamental & Clinical Pharmacology29 citations Open access
Semantic Scholar
Characteristics and outcome of SARS-CoV-2 infection in cancer patients.
C. Basse, Sarah Diakité, V. Servois, M. Frelaut +19 more
2020medRxiv28 citations Open access
Semantic Scholar
Advances in theranostic biomarkers for tumor immunotherapy.
A. Bellesoeur, Nouritza Torossian, S. Amigorena, E. Romano
2020Current Opinion in Chemical Biology27 citations Open access
Semantic Scholar
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy
Caroline Malhaire, Fatine Selhane, M. Saint-Martin, Vincent Cockenpot +12 more
2023European Radiology23 citations Open access
Semantic Scholar
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
B. Porte, M. Carton, F. Lerebours, E. Brain +6 more
2020Breast19 citations Open access
Semantic Scholar
Choosing a career in oncology: results of a nationwide cross-sectional study
J. Faivre, J. Bibault, A. Bellesoeur, J. Salleron +14 more
2018BMC Medical Education19 citations Open access
Semantic Scholar
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer
A. Bellesoeur, Edith Carton, O. Mir, L. Groussin +4 more
2014Investigational new drugs18 citations
Semantic Scholar
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours
R. Cohen, L. H. Preta, V. Joste, E. Curis +14 more
2019British Journal of Clinical Pharmacology17 citations Open access
Semantic Scholar
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib
Gaёlle Noe, A. Bellesoeur, A. Thomas-Schoemann, Savithri Rangarajan +9 more
2016OncoTarget17 citations Open access
Semantic Scholar
Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
R. Seban, L. Champion, A. Bellesoeur, A. Vincent-Salomon +1 more
2023Journal of Nuclear Medicine12 citations Open access
Semantic Scholar
ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy.
I. Ray-Coquard, A. Leary, F. Bigot, L. Montané +16 more
202110 citations
Semantic Scholar
Sorafenib for patients with differentiated thyroid cancer.
P. Boudou-Rouquette, A. Thomas-Schoemann, A. Bellesoeur, F. Goldwasser
2015The Lancet9 citations
Semantic Scholar
BRCA2 Loss‐of‐Function and High Sensitivity to Cisplatin‐Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine
C. Tlemsani, É. Pasmant, P. Boudou-Rouquette, A. Bellesoeur +9 more
2018American Journal of the Medical Sciences8 citations
Semantic Scholar
Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
A. Bellesoeur, I. Gataa, A. Jouinot, Sarah El Mershati +13 more
2021Cancer Chemotherapy and Pharmacology7 citations Open access
Semantic Scholar
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
G. Noé, A. Bellesoeur, L. Golmard, A. Thomas-Schoemann +8 more
2019Cancers5 citations Open access
Semantic Scholar
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
Clélia Chalumeau, M. Carton, A. Eeckhoutte, S. Ballet +7 more
2022Cancers4 citations Open access
Semantic Scholar
[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
Marie-Sophie Minot-This, A. Bellesoeur
2021Bulletin du Cancer4 citations
Semantic Scholar
Adverse events of targeted therapies approved for women's cancers
M. Saint-Ghislain, C. Levenbruck, A. Bellesoeur
2021International Journal of Women's Dermatology4 citations Open access
Semantic Scholar
Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration.
A. Bellesoeur, I. Gataa, A. Jouinot, S. El Mershati +7 more
2018Annals of Oncology4 citations Open access
Semantic Scholar
Abstract 4546: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort
D. Damotte, J. Arrondeau, P. Boudou-Rouquette, A. Lupo +14 more
2018Clinical research4 citations
Semantic Scholar
Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma
A. Puszkiel, G. Noé, A. Thomas-Schoemann, A. Bellesoeur +4 more
20173 citations
Semantic Scholar
Abstract P2-16-35: Impact of neoadjuvant chemotherapy on survival in luminal B tumours: A propensity score weighted analysis
E. Laas, T. Gaillard, J. Féron, J. Pierga +10 more
20202 citations
Semantic Scholar
Biomarkers in cancer immunotherapy: analysis of clinical, histological and immunohistochemical factors associated with PD-L1 status
A. Bellesoeur, C. Massard, J. Soria
20162 citations Open access
Semantic Scholar
Abstract PS11-02: [18F]fluoroestradiol (FES) PET/CT to guide 2nd line treatment decision in patients with ER-positive HER2-negative advanced breast cancer (ABC) progressing on 1st line aromatase inhibitor and CDK4/6 inhibitor: early results of the ESTROTIMP trial
F. Bidard, Bidard, R. Seban, S. M. van de Ven +11 more
2025Clinical Cancer Research1 citations
Semantic Scholar
113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database
C. Chalumeau, J. Pierga, G. Pierron, S. Ballet +7 more
20211 citations Open access
Semantic Scholar
Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma.
A. Jouinot, Bernard Royer, Sotheara Moeung, Etienne Chatelut +6 more
2018Annals of Oncology1 citations Open access
Semantic Scholar
Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: A retrospective monocentric cohort study
Lucia Parlati, A. V. Pichard, H. Alain, A. Bellesoeur +17 more
20181 citations
Semantic Scholar
Individualized Pazopanib Dosing—Letter
A. Bellesoeur, P. Boudou-Rouquette, A. Thomas-Schoemann, C. Joly +4 more
2017Clinical Cancer Research1 citations Open access
Semantic Scholar
Les jeunes oncologues au service de la cancérologie de demain
J. Wassermann, A. Bellesoeur
20131 citations
Semantic Scholar
Excavated pneumonia: an unusual suspect
A. Bellesoeur, L. Chalumeau-Lemoine, F. Blot
2013Intensive Care Medicine1 citations Open access
Semantic Scholar
ECLECTIC: 18 F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.
F. Bidard, A. Bellesoeur, N. Hajjaji, Elise Rowinski +8 more
2024Journal of Clinical Oncology0 citations
Semantic Scholar
Oral etoposide and trastuzumab in HER2-positive metastatic breast cancer: a retrospective study at Institut Curie Hospitals.
F. Lerebours, Clélia Chalumeau, M. Carton, A. Eeckhoutte +7 more
20220 citations Open access
Semantic Scholar
Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study
D. Loirat, Juliette Logeart, P. Vaflard, Aurélie Noret +13 more
2022Cancer Research0 citations
Semantic Scholar
Abstract PS10-40: Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
B. Porte, M. Carton, D. Loirat, F. Bidard +4 more
20210 citations
Semantic Scholar
Abstract P2-16-36: Survival benefit of neoadjuvant chemotherapy versus adjuvant chemotherapy in HER2-positive early breast cancer: A propensity score-weighted analysis
E. Laas, A. Bresset, J. Féron, J. Pierga +10 more
20200 citations
Semantic Scholar
Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.
P. Boudou-Rouquette, Ithar Gataa, A. Jouinot, S. de Percin +10 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract 4107: Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab efficacy in advanced non-small cell lung cancer
M. T. Meyo, A. Jouinot, E. Giroux-Leprieur, E. Fabre +10 more
2019Clinical research0 citations
Semantic Scholar
Clinical and pharmacological parameters associated with nivolumab toxicity.
L. Hirsch, A. Bellesoeur, M. Allard, P. Boudou-Rouquette +11 more
20180 citations
Semantic Scholar
Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention.
P. Boudou-Rouquette, Ariane de Buyer, C. Tlemsani, S. Chauffour +10 more
20180 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Goldwasser×22
Invite
F. Goldwasser — researcher profile on SciRah
P. Boudou-Rouquette×16
Invite
P. Boudou-Rouquette — researcher profile on SciRah
B. Blanchet×16
Invite
B. Blanchet — researcher profile on SciRah
J. Alexandre×16
Invite
J. Alexandre — researcher profile on SciRah

A. Thomas-Schoemann

×15

Invite

A. Thomas-Schoemann — researcher profile on SciRah

Invite

M. Vidal — researcher profile on SciRah

J. Arrondeau×10

Invite

J. Arrondeau — researcher profile on SciRah

Invite

F. Bidard — researcher profile on SciRah

Invite

C. Tlemsani — researcher profile on SciRah

Invite

A. Jouinot — researcher profile on SciRah

Invite

P. Vuagnat — researcher profile on SciRah

Invite

P. Cottu — researcher profile on SciRah